On Tuesday, Conmed Corp (NYSE: CNMD) opened lower -7.89% from the last session, before settling in for the closing price of $43.46. Price fluctuations for CNMD have ranged from $38.32 to $74.70 over the past 52 weeks.
Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 34.38%. Company’s average yearly earnings per share was noted 7.91% at the time writing. With a float of $30.03 million, this company’s outstanding shares have now reached $30.96 million.
Conmed Corp (CNMD) Breakdown of a Key Holders of the stock
A key investor’s attitude towards the stock of the Medical Devices industry is another important factor to consider. The insider ownership of Conmed Corp is 3.04%, while institutional ownership is 109.21%. The most recent insider transaction that took place on Nov 21 ’25, was worth 10,591. In this transaction Chief Information Officer of this company sold 257 shares at a rate of $41.21, taking the stock ownership to the 0 shares. Before that another transaction happened on Nov 21 ’25, when Company’s Officer proposed sale 257 for $41.21, making the entire transaction worth $10,591.
Conmed Corp (CNMD) Recent Fiscal highlights
If we go through the results of last quarter, which was made public on 12/31/2024, the company posted 1.34 earnings per share (EPS) for the quarter, besting the agreed prediction (set at 1.2) by 0.14. Wall Street market experts anticipate that the next fiscal year will bring earnings of 0.94 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 7.91% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 6.31% during the next five years compared to 34.38% growth over the previous five years of trading.
Conmed Corp (NYSE: CNMD) Trading Performance Indicators
Check out the current performance indicators for Conmed Corp (CNMD). In the past quarter, the stock posted a quick ratio of 0.95. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 0.92. Likewise, its price to free cash flow for the trailing twelve months is 8.32.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 2.06, a number that is poised to hit 1.32 in the next quarter and is forecasted to reach 4.46 in one year’s time.
